Egfr Inhibitors
Egfr Inhibitors - Related Videos
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
02:08
Assessing Bacterial Swarming Using a Gradient Inhibitor Plate
0 Views •
2025
Source: Guo, S., et al. Quantifying Bacterial Surface Swarming Motility on Inducer Gradient Plates. J. Vis. Exp. (2022).This video demonstrates the use of a double-layer gradient swarm plate to study bacterial swarming behavior under varying inhibitor concentrations. A plate with a gradient-forming inhibitor in the bottom layer is inoculated with bacteria and incubated. Images are captured at regular intervals to analyze the effect of inhibitor concentration on bacterial swarming.
FAQs
The two major classes interrupt EGFR signaling at different points. Monoclonal antibodies act at the receptor level by preventing epidermal growth factor from activating it, whereas small-molecule inhibitors target the receptor’s intracellular tyrosine kinase activity. This distinction lets researchers compare extracellular blockade with intracellular enzymatic inhibition when studying how receptor signals control cancer-cell behavior.
Blocking the receptor’s initiating signal matters because EGFR activity feeds downstream pathways that promote cell division and survival. Inhibiting those pathways can therefore reduce signals that sustain abnormal growth, rather than merely altering a surface receptor’s status. This downstream perspective helps connect a molecular intervention with changes in cancer biology.
EGFR inhibitors can also be examined through the receptor’s role in differentiation, the process by which cells acquire specialized characteristics. Because EGFR regulates growth, survival, and differentiation, disrupting its signaling may reveal how one receptor coordinates several cellular outcomes. Researchers can use this relationship to interpret inhibitor effects as changes in cell-state regulation, not only proliferation.
Predictive mutations and other biomarkers help identify tumors in which EGFR signaling is especially relevant to treatment response. Their value is not simply descriptive: they connect a tumor’s molecular features with the likely importance of the pathway being targeted. Incorporating such markers makes EGFR inhibitor research more biologically informed and supports investigation of why responses differ.
Treatment resistance is a distinct research outcome rather than a minor variation in response. Researchers investigate why cancer biology can remain viable despite targeting abnormal EGFR signaling, using resistance as a way to examine pathway dependence and changes in treatment effectiveness. This context helps explain why a drug’s initial activity may not predict its longer-term value.
Within biology, EGFR inhibitors serve as perturbations of receptor-mediated communication. Their effects can help link receptor activation or kinase activity to downstream signals governing division, survival, and differentiation. Studying these links gives researchers a way to ask which cellular outcomes depend on EGFR signaling and how abnormal communication contributes to cancer.